Another set of data validate the proposed new prostate cancer grading system

Another independent study has validated the proposed new prostate cancer grading system developed by members of the International Society of Urologic Pathologists (ISUP) and discussed previously on this web site. … READ MORE …

Another new article validates proposed new IUSP grading system

Another new article (to be published in European Urology) has used data from > 25,000 patients to validate the proposed IUSP grading system, scheduled to replace the Gleason grading system over the next few years. … READ MORE …

Predictive accuracy of the new ISUP grading system in a nationwide patient cohort

A paper in European Urology has provided us with additional early data on the applicability of the new ISUP grading system scheduled to replace the Gleason grading system over the next few years. … READ MORE …

The new ISUP grading system and its prognostic value

Back in June this year we provided an initial, basic introduction to the new, grouped, pathologic staging system approved by the International Society of Urologic Pathologists as a replacement for the Gleason grading system over the next few years. … READ MORE …

Toward a new prostate cancer grading system — step 1

In the most recent issue of AUA News, Dr. Jonathon Epstein of  Johns Hopkins — unarguably one of the world’s leading prostate cancer pathologists — has laid out the general principles behind a new, validated, prostate cancer grading system that is designed and intended to replace the traditional Gleason grading system over the next few years. … READ MORE …

Prostate cancer news reports: Sunday, January 10, 2010

Today’s news reports address studies dealing with the following issues:

  • Re-validation of the PCPT-based prostate cancer risk calculator in contemporary patients
  • Can the SPECT/CT-enhanced Prostascint test replace prostate biopsy?
  • Who should be eligible for active surveillance protocols?
  • Predicting survival of hormone-refractory patients progressing after first-line, docetaxel-based chemotherapy … READ MORE …